Related Experiment Video
Updated: Mar 10, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
New Insights On Ablation Of Persistent Atrial Fibrillation: Evidence From The SARA Trial
Felipe Bisbal Md1, Lluís Mont Md PhD1
1Unitat de Fibril•lació Auricular (UFA). Hospital Clinic, Barcelona, Spain.
Insights
Catheter ablation effectively treats paroxysmal atrial fibrillation (AF). However, evidence for its efficacy in persistent AF is limited, necessitating further research into optimal treatment strategies.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Pulmonary vein firing is a key trigger for atrial fibrillation (AF).
- Catheter ablation is established for paroxysmal AF but less so for persistent AF.
- Limited evidence exists for persistent AF ablation, primarily from non-randomized studies.
Approach:
- This article reviews current scientific evidence on persistent AF treatment.
- It discusses existing therapeutic approaches for persistent AF.
- Key findings from the SARA trial are presented and contextualized.
Key Points:
- Paroxysmal AF ablation is well-supported by randomized trials.
- Persistent AF ablation efficacy is less established, with limited high-quality evidence.
- The SARA trial provides new data on persistent AF management.
Conclusions:
- Further research is needed to solidify the role of catheter ablation in persistent AF.
- Optimal strategies for persistent AF treatment require continued investigation.
- The SARA trial contributes valuable insights into managing persistent AF.
Abstract:
Since Haissaguerre et al first described the pathogenic role of pulmonary vein firing as a crucial mechanism triggering atrial fibrillation, catheter ablation has been recommended as a curative treatment. Several trials have demonstrated that ablation is an effective treatment in most patients with paroxysmal atrial fibrillation and low-grade remodelled atria. In patients with persistent AF, there is substantially less evidence, mostly based on non-randomized studies, supporting this recommendation. The available scientific evidence as well as the current approaches to treating persistent AF patients are discussed in this article. Further, we describe the main findings of the SARA trial and put them into perspective.
